Patients who are being treated for a leading cause of blindness among the elderly might be able to scale back on eye injections if trials confirm the potential of an eye drop being developed by a small New York-based company.Ohr Pharmaceutical Inc's Squalamine drug - an eye drop, as opposed to the injection therapies sold by Regeneron Pharmaceuticals Inc and Roche Holdings - doesn't necessarily need to outsell its formidable competitors.Simply proving that the drop can be used as a complementary treatment to Regeneron's Eylea or Roche's Lucentis could be enough to ensure commercial success for Ohr in treating wet age-related macular degeneration (AMD).The main challenge will be to demonstrate Squalamine's ability to travel to the back of the eye and stay there long enough to be absorbed. A mid-stage clinical trial is under way.
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Shares of REGN fell by 0.31% or $-0.91/share to $295.78. In the past year, the shares have traded as low as $154.16 and as high as $319.83. On average, 780803 shares of REGN exchange hands on a given day and today's volume is recorded at 167953.
Source
